Document Detail

Aberrant PSA glycosylation-a sweet predictor of prostate cancer.
MedLine Citation:
PMID:  23318363     Owner:  NLM     Status:  Publisher    
Prostate cancer-the most commonly diagnosed cancer in men worldwide-can have a substantial effect on quality of life, regardless of the route the cancer takes. The serum PSA assay is the current gold standard option for diagnosing prostate cancer. However, a growing body of evidence suggests that PSA screening for prostate cancer results in extensive overdiagnosis and overtreatment. It is increasingly evident that the potential harm from overdiagnosis (in terms of unnecessary biopsies) must be weighed against the benefit derived from the early detection and treatment of potentially fatal prostate cancers. Rapid screening methods have been used to analyse glycosylation patterns on glycoproteins in large cohorts of patients, enabling the identification of a new generation of disease biomarkers. Changes to the expression status of certain glycan structures are now widely thought to be common features of tumour progression. In light of this development, much research has focused on the potential role of altered PSA glycosylation patterns in discriminating between significant and insignificant prostate cancers, with the aim of developing a more reliable diagnostic tool than the current serum PSA test.
Sarah Gilgunn; Paul J Conroy; Radka Saldova; Pauline M Rudd; Richard J O'Kennedy
Related Documents :
24659913 - Short-, intermediate-, and long-term quality of life outcomes following radical prostat...
24415363 - Cancer cachexia update in head and neck cancer: definitions and diagnostic features.
8338283 - Immediate, bilateral transverse rectus abdominis musculocutaneous (tram) flap reconstru...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-15
Journal Detail:
Title:  Nature reviews. Urology     Volume:  -     ISSN:  1759-4820     ISO Abbreviation:  Nat Rev Urol     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-15     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101500082     Medline TA:  Nat Rev Urol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
School of Biotechnology, Dublin City University, Dublin 9, Ireland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Familial prostate cancer: the damage done and lessons learnt.
Next Document:  Surgical management of female SUI: is there a gold standard?